BioMedWire Editorial Coverage: Oncology research is moving through one of its most active stretches in years. DNA Damage Response (“DDR”) inhibitors, a ...

Jared Holz, health care sector strategist at Mizuho Securities, joins 'Squawk on the Street' to discuss GSK’s plan to acquire Nuvalent for $10.6 billion, his view on Eli Lilly, and more. Got a ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — GSK said Tuesday it would ...

Jared Holz, health care sector strategist at Mizuho Securities, joins 'Squawk on the Street' to discuss GSK’s plan to acquire Nuvalent for $10.6 billion, his view on Eli Lilly, and more. MAGA melts ...

GSK (GSK) reported better-than-expected financials for Q1 2026 on Wednesday as sales from its HIV and cancer medicines offset a sales decline for its general medicines, including its respiratory ...

GSK (GSK) is preparing a high-stakes push into oncology, lining up five late-stage trials at once for a promising cancer drug as new CEO Luke Miels seeks to reshape the company’s historically cautious ...

GSK struck a $950 million deal to buy Canada’s 35Pharma, a biopharmaceutical company developing cardiopulmonary treatments, as the U.K. drugmaker seeks to bolster its exposure to diseases linked to ...

GSK Plc’s new chief executive officer plans to speed up research and development and look for acquisitions as the British drugmaker tries to convince investors it can offset a looming patent cliff.

LONDON, Feb 4 (Reuters) - GSK's new CEO Luke ‌Miels said on Wednesday that the drugmaker will ‌aim to lift sales growth and speed up work on new medicines in its next phase of growth through a sharper ...

With star checkpoint inhibitors like Keytruda and Opdivo now sporting subcutaneous formulations, GSK has struck a deal aimed at ensuring its own PD-1 stalwart doesn’t miss out on the action. GSK, ...